186 related articles for article (PubMed ID: 18228523)
1. PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck.
Morris LG; Wen YH; Nonaka D; DeLacure MD; Kutler DI; Huan Y; Wang BY
Head Neck; 2008 Jun; 30(6):771-5. PubMed ID: 18228523
[TBL] [Abstract][Full Text] [Related]
2. HMB-45 may be a more sensitive maker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanomas.
Yu CH; Chen HH; Liu CM; Jeng YM; Wang JT; Wang YP; Liu BY; Sun A; Chiang CP
J Oral Pathol Med; 2005 Oct; 34(9):540-5. PubMed ID: 16138892
[TBL] [Abstract][Full Text] [Related]
3. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations.
Sheffield MV; Yee H; Dorvault CC; Weilbaecher KN; Eltoum IA; Siegal GP; Fisher DE; Chhieng DC
Am J Clin Pathol; 2002 Dec; 118(6):930-6. PubMed ID: 12472287
[TBL] [Abstract][Full Text] [Related]
4. HMB-45 and Melan-A are useful in the differential diagnosis between granular cell tumor and malignant melanoma.
Gleason BC; Nascimento AF
Am J Dermatopathol; 2007 Feb; 29(1):22-7. PubMed ID: 17284958
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical evaluation of necrotic malignant melanomas.
Nonaka D; Laser J; Tucker R; Melamed J
Am J Clin Pathol; 2007 May; 127(5):787-91. PubMed ID: 17439838
[TBL] [Abstract][Full Text] [Related]
6. [Reactivity of five different antibodies with benign and malignant melanocytic lesions].
Plótár V; Szentirmay Z; Orosz Z
Magy Onkol; 2008 Dec; 52(4):363-73. PubMed ID: 19068464
[TBL] [Abstract][Full Text] [Related]
7. Microphthalmia transcription factor immunohistochemistry: a useful diagnostic marker in the diagnosis and detection of cutaneous melanoma, sentinel lymph node metastases, and extracutaneous melanocytic neoplasms.
O'Reilly FM; Brat DJ; McAlpine BE; Grossniklaus HE; Folpe AL; Arbiser JL
J Am Acad Dermatol; 2001 Sep; 45(3):414-9. PubMed ID: 11511840
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical identification of canine melanocytic neoplasms with antibodies to melanocytic antigen PNL2 and tyrosinase: comparison with Melan A.
Ramos-Vara JA; Miller MA
Vet Pathol; 2011 Mar; 48(2):443-50. PubMed ID: 20858741
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical expression of melanocytic antigen PNL2, Melan A, S100, and PGP 9.5 in equine melanocytic neoplasms.
Ramos-Vara JA; Frank CB; DuSold D; Miller MA
Vet Pathol; 2014 Jan; 51(1):161-6. PubMed ID: 23370093
[TBL] [Abstract][Full Text] [Related]
10. Primary nasal mucosal melanoma in Brazil: clinicopathologic and immunohistochemical study of 12 patients.
Benevenuto de Andrade BA; Piña AR; León JE; Paes de Almeida O; Altemani A
Ann Diagn Pathol; 2012 Oct; 16(5):344-9. PubMed ID: 22425483
[TBL] [Abstract][Full Text] [Related]
11. [Sinonasal mucosal melanoma].
Pomar Blanco P; San Román Carbajo J; Bouso Montero M; Martín Villares C; Fernández Pello M; Tapia Risueño M
An Otorrinolaringol Ibero Am; 2007; 34(4):349-58. PubMed ID: 17844954
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical diagnosis of canine oral amelanotic melanocytic neoplasms.
Smedley RC; Lamoureux J; Sledge DG; Kiupel M
Vet Pathol; 2011 Jan; 48(1):32-40. PubMed ID: 21078882
[TBL] [Abstract][Full Text] [Related]
13. PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen.
Rochaix P; Lacroix-Triki M; Lamant L; Pichereaux C; Valmary S; Puente E; Al Saati T; Monsarrat B; Susini C; Buscail L; Delsol G; Voigt JJ
Mod Pathol; 2003 May; 16(5):481-90. PubMed ID: 12748255
[TBL] [Abstract][Full Text] [Related]
14. Malignant melanoma with neuroendocrine differentiation: clinical, histological, immunohistochemical and ultrastructural features of three cases.
Eyden B; Pandit D; Banerjee SS
Histopathology; 2005 Oct; 47(4):402-9. PubMed ID: 16178895
[TBL] [Abstract][Full Text] [Related]
15. Expression of melanocytic differentiation markers in malignant melanomas of the oral and sinonasal mucosa.
Prasad ML; Jungbluth AA; Iversen K; Huvos AG; Busam KJ
Am J Surg Pathol; 2001 Jun; 25(6):782-7. PubMed ID: 11395556
[TBL] [Abstract][Full Text] [Related]
16. SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar.
Ramos-Herberth FI; Karamchandani J; Kim J; Dadras SS
J Cutan Pathol; 2010 Sep; 37(9):944-52. PubMed ID: 20653825
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical characteristics of melanoma.
Ohsie SJ; Sarantopoulos GP; Cochran AJ; Binder SW
J Cutan Pathol; 2008 May; 35(5):433-44. PubMed ID: 18399807
[TBL] [Abstract][Full Text] [Related]
18. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response.
Ugurel S; Houben R; Schrama D; Voigt H; Zapatka M; Schadendorf D; Bröcker EB; Becker JC
Clin Cancer Res; 2007 Nov; 13(21):6344-50. PubMed ID: 17975146
[TBL] [Abstract][Full Text] [Related]
19. An immunohistochemical comparison between MiTF and MART-1 with Azure blue counterstaining in the setting of solar lentigo and melanoma in situ.
Hillesheim PB; Slone S; Kelley D; Malone J; Bahrami S
J Cutan Pathol; 2011 Jul; 38(7):565-9. PubMed ID: 21362015
[TBL] [Abstract][Full Text] [Related]
20. PNL2: an adjunctive biomarker for renal angiomyolipomas and perivascular epithelioid cell tumours.
Gulavita P; Fletcher CDM; Hirsch MS
Histopathology; 2018 Feb; 72(3):441-448. PubMed ID: 28837273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
